Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
- Conditions
- Migraine
- Interventions
- Registration Number
- NCT06241313
- Lead Sponsor
- AbbVie
- Brief Summary
A migraine attack is a moderate or severe headache that usually occurs on one side of the head and is often accompanied by throbbing, sensitivity to light, sensitivity to sound, nausea, or other symptoms. The main goal of the study is to see if atogepant is effective, safe, and well-tolerated in treating migraine attacks quickly.
Atogepant is a medicine currently approved for the preventive treatment of migraine in adults and has been shown to be effective and well tolerated when taken daily to prevent migraine attacks. This study includes double-blind phase means that neither the participants nor the study doctors know who is given which study treatment (atogepant or placebo) followed by an open-label phase meaning that both participants and study doctors know which study treatment is given. All participants will receive atogepant during the open-label part of the study. This study will include 1300 participants aged 18-75 years with a history of migraine at approximately 160 sites across the world.
All participants will receive both atogepant and placebo to treat qualifying migraines. At the start of the study, participants will be randomized to 1 of 4 dosing sequences to determine when they will receive atogepant and when they will receive placebo during the study. After treating 4 qualifying migraine attacks, participants will receive open-label atogepant for any additional migraine attacks they have until the end of the study (Week 24).
There may be a bigger responsibility for participants in this study than there would be in participants receiving standard of care treatment. participants will attend regular visits during the study at a hospital or clinic, as well as telephone visits, and the effects of treatment will be checked by completion of questionnaires in an electronic diary, medical assessments, blood tests, and checking for side effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1300
- History of migraine (with or without aura) according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) for >= 12 months prior to Visit 1/Screening.
- History of 2 to 8 migraine attacks of moderate to severe headache pain in each of the 3 months prior to Visit 1/Screening per investigator judgment.
- Migraine onset before the age of 50.
- History of migraines lasting between 4 and 72 hours when untreated or treated unsuccessfully and migraine episodes separated by at least 48 hours of headache pain freedom.
- History of an average of 15 or more headache days per month in the 6 months prior to Visit 1/Screening per the investigator's judgment, or a current diagnosis of chronic migraine as defined by ICHD-3.
- Require hospital/emergency room treatment for migraine attacks on 3 or more occasions within 6 months prior to Visit 1/Screening.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Sequence 3 Atogepant Participants will receive both atogepant and placebo to treat qualifying migraines. Sequence 3 Placebo for Atogepant Participants will receive both atogepant and placebo to treat qualifying migraines. Sequence 1 Placebo for Atogepant Participants will receive both atogepant and placebo to treat qualifying migraines. Sequence 4 Atogepant Participants will receive both atogepant and placebo to treat qualifying migraines. Sequence 4 Placebo for Atogepant Participants will receive both atogepant and placebo to treat qualifying migraines. Sequence 2 Placebo for Atogepant Participants will receive both atogepant and placebo to treat qualifying migraines. Sequence 2 Atogepant Participants will receive both atogepant and placebo to treat qualifying migraines. Sequence 1 Atogepant Participants will receive both atogepant and placebo to treat qualifying migraines.
- Primary Outcome Measures
Name Time Method Percentage of Participants Achieving Pain Freedom at 2 Hours After the Double-Blind (DB) Dose for the First Attack Approximately 16 Weeks Pain freedom is defined as a reduction in headache severity from moderate/severe at baseline (predose) to no pain.
- Secondary Outcome Measures
Name Time Method Percentage of Participants With Absence of Most Bothersome Migraine-associated Symptom (MBS) at 2 Hours After the Double-Blind (DB) Dose for the First Attack Approximately 16 Weeks Percentage of Participants With Absence of Most Bothersome Migraine-associated Symptom (MBS) will be assessed.
Percentage of Participants Achieving Pain Relief at 2 Hours After the Double-Blind (DB) Dose for the First Attack Approximately 16 Weeks Pain relief is defined as the reduction of a moderate/severe migraine headache at baseline \[predose\] to a mild headache or to no headache.
Percentage of Participants Achieving Sustained Pain Relief From 2 to 24 Hours After DB Dose for the First Attack Approximately 16 Weeks Sustained pain relief is defined as pain relief at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a moderate/severe headache from 2 to 24 hours.
Percentage of Participants Achieving Sustained Pain Relief From 2 to 48 Hours After DB Dose for the First Attack Approximately 16 Weeks Sustained pain relief is defined as pain relief at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a moderate/severe headache from 2 to 24 hours.
Percentage of Participants With Use of Rescue Medication Within 24 Hours After DB Dose for the First Attack Approximately 16 Weeks Percentage of participants with use of rescue medication within 24 hours after the DB dose for the first attack will be assessed.
Percentage of Participants With Ability to Function Normally at 2 Hours After DB Dose for the First Attack Approximately 16 Weeks Percentage of participants with ability to function normally at 2 hours after the DB dose for the first attack will be assessed.
Percentage of Participants Achieving Sustained Pain Freedom From 2 to 48 Hours After DB Dose for the First Attack Approximately 16 Weeks Sustained pain freedom is defined as pain freedom at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a mild/moderate/severe headache from 2 to 24 hours.
Percentage of Participants With Absence of Photophobia at 2 Hours After the DB Dose for the First Attack Approximately 16 Weeks Photophobia is defined as sensitivity to light.
Percentage of Participants With Absence of Phonophobia at 2 Hours After the DB Dose for the First Attack Approximately 16 Weeks Phonophobia is defined as sensitivity to sound.
Percentage of Participants Achieving Pain Freedom at 8 Hours After the DB Dose for the First Attack Approximately 16 Weeks Pain freedom is defined as a reduction in headache severity from moderate/severe at baseline (predose) to no pain.
Percentage of Participants With Ability to Function Normally at 8 Hours After DB Dose for the First Attack Approximately 16 Weeks Percentage of participants with ability to function normally at 8 hours after the DB dose for the first attack will be assessed.
Percentage of Participants Achieving Pain Relief at 1 Hour After the Double-Blind (DB) Dose for the First Attack Approximately 16 Weeks Pain relief is defined as the reduction of a moderate/severe migraine headache at baseline \[predose\] to a mild headache or to no headache.
Percentage of Participants With Absence of Nausea at 2 Hours After the Double-Blind (DB) Dose for the First Attack Approximately 16 Weeks Percentage of participants with absence of nausea at 2 hours after the DB dose for the first attack.
Percentage of Participants Achieving Pain Relief at 30 Minutes After the Double-Blind (DB) Dose for the First Attack Approximately 16 Weeks Pain relief is defined as the reduction of a moderate/severe migraine headache at baseline \[predose\] to a mild headache or to no headache.
Percentage of Participants With Ability to Function Normally at 1 Hour After DB Dose for the First Attack Approximately 16 Weeks Percentage of participants with ability to function normally at 1 hour after the DB dose for the first attack will be assessed.
Percentage of Participants Achieving Pain Freedom at 2 Hours After Receiving DB Atogepant for at least 2 out of 3 Attacks Approximately 16 Weeks Pain freedom is defined as a reduction in headache severity from moderate/severe at baseline (predose) to no pain.
Percentage of Participants Achieving Sustained Pain Freedom From 2 to 24 Hours After DB Dose for the First Attack Approximately 16 Weeks Sustained pain freedom is defined as pain freedom at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a mild/moderate/severe headache from 2 to 24 hours.
Percentage of Participants Achieving Sustained Pain Relief From 2 to 48 Hours After Receiving DB Atogepant for at least 2 out of 3 Attacks Approximately 16 Weeks Sustained pain relief is defined as pain relief at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a moderate/severe headache from 2 to 24 hours.
Percentage of Participants Achieving Sustained Pain Freedom From 2 to 24 Hours After Receiving DB Atogepant for at least 2 out of 3 Attacks Approximately 16 Weeks Sustained pain freedom is defined as pain freedom at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a mild/moderate/severe headache from 2 to 24 hours.
Percentage of Participants Achieving Sustained Pain Freedom From 2 to 48 Hours After Receiving DB Atogepant for at least 2 out of 3 Attacks Approximately 16 Weeks Sustained pain freedom is defined as pain freedom at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a mild/moderate/severe headache from 2 to 24 hours.
Percentage of Participants Achieving Pain Relief at 2 Hours After Receiving Double-Blind (DB) Atogepant for at least 2 out of 3 Attacks Approximately 16 Weeks Pain relief is defined as the reduction of a moderate/severe migraine headache at baseline \[predose\] to a mild headache or to no headache.
Percentage of Participants Achieving Sustained Pain Relief From 2 to 24 Hours After Receiving DB Atogepant for at least 2 out of 3 Attacks Approximately 16 Weeks Sustained pain relief is defined as pain relief at 2 hours after the DB dose with no administration of rescue medication and no occurrence of a moderate/severe headache from 2 to 24 hours.
Trial Locations
- Locations (148)
Unidade Local de Saude de Santo Antonio, E.P.E. /ID# 258140
🇵🇹Porto, Portugal
Semmelweis Egyetem /ID# 258800
🇭🇺Budapest, Hungary
UNO Medical Trials /ID# 259186
🇭🇺Budapest, Hungary
S-Medicon Kft /ID# 258547
🇭🇺Budapest, Hungary
Istituto Neurologico Mediterraneo Neuromed /ID# 258593
🇮🇹Pozzilli, Isernia, Italy
ASL 1 Abruzzo - Ospedale SS. Filippo and Nicola /ID# 258590
🇮🇹Avezzano, L Aquila, Italy
IRCCS Ospedale San Raffaele /ID# 258592
🇮🇹Milan, Milano, Italy
Istituto Auxologico Italiano - Irccs /ID# 258623
🇮🇹Milan, Milano, Italy
A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 258591
🇮🇹Torino, Piemonte, Italy
Univ. of Bologna-IRCCS-Istituto delle Scienze Neurologiche /ID# 261089
🇮🇹Bologna, Italy
ASST degli Spedali Civili di Brescia /ID# 258594
🇮🇹Brescia, Italy
ICOT Istituto Marco Pasquali /ID# 258621
🇮🇹Latina, Italy
Fondazione Mondino Istituto Neurologico Nazionale a Carattere Scientifico IRCCS /ID# 258589
🇮🇹Pavia, Italy
Fondazione Policlinico Universitario Campus Bio-Medico /ID# 258588
🇮🇹Roma, Italy
H.-Hartziekenhuis Lier /ID# 257577
🇧🇪Lier, Belgium
Cabinet Prive Dr Sava /ID# 257581
🇧🇪Saint-Nicolas, Belgium
Ospedale San Paolo - ASL2 /ID# 258622
🇮🇹Savona, Italy
Tokyo Dental College Ichikawa General Hospital /ID# 259570
🇯🇵Ichikawa-shi, Chiba, Japan
Higashi Sapporo Neurology And Neurosurgery Clinic /ID# 262708
🇯🇵Sapporo-shi, Hokkaido, Japan
The first affiliated hospital of bengbu medical college /ID# 258758
🇨🇳Bengbu, Anhui, China
Peking University Third Hospital /ID# 259573
🇨🇳Beijing, Beijing, China
The University Of Hong Kong - Shenzhen Hospital /ID# 258462
🇨🇳Shenzhen, Guangdong, China
Hebei General Hospital /ID# 258583
🇨🇳Shijiazhuang, Hebei, China
Zhengzhou People's Hospital /ID# 258670
🇨🇳Zhengzhou, Henan, China
Zhuzhou Central Hospital /ID# 260076
🇨🇳Zhuzhou, Hunan, China
The Second Affiliated Hospital of Soochow University /ID# 259551
🇨🇳Suzhou, Jiangsu, China
Jiangxi Pingxiang People's Hospital /ID# 258652
🇨🇳Pingxiang, Jiangxi, China
Beijing Friendship Hospital /ID# 258830
🇨🇳Beijing, Beijing, China
The Second Xiangya Hospital of Central South University /ID# 260623
🇨🇳Changsha, Hunan, China
The Second Affiliated Hospital of Nanjing Medical University /ID# 258648
🇨🇳Nanjing, Jiangsu, China
Ikeda Neurosurgical Clinic /ID# 259085
🇯🇵Kasuga-shi, Fukuoka, Japan
Xuanwu Hospital Capital Medical University /ID# 258510
🇨🇳Beijing, Beijing, China
Chinese PLA General Hospital /ID# 257540
🇨🇳Beijing, Beijing, China
Guangzhou First People's Hospital /ID# 258656
🇨🇳Guangzhou, Guangdong, China
The First Affiliated Hospital of Soochow University /ID# 258783
🇨🇳Suzhou, Jiangsu, China
Umenotsuji Clinic /ID# 258717
🇯🇵Kochi-shi, Kochi, Japan
Sendai Headache and Neurology Clinic Medical Corporation /ID# 258862
🇯🇵Sendai-shi, Miyagi, Japan
Peking University First Hospital /ID# 258672
🇨🇳Xicheng District, Beijing, China
Fujian Medical University Union Hospital /ID# 259575
🇨🇳Fuzhou, Fujian, China
The First Affiliated Hospital of Xiamen University /ID# 259576
🇨🇳Xiamen, Fujian, China
Lanzhou University Second Hospital /ID# 259667
🇨🇳Lanzhou, Gansu, China
Tominaga Clinic /ID# 258553
🇯🇵Osaka-shi, Osaka, Japan
DOI Internal Medicine-Neurology Clinic /ID# 259009
🇯🇵Hiroshima, Japan
Tatsuoka Neurology Clinic /ID# 258771
🇯🇵Kyoto, Japan
Hallym University Dongtan Sacred Heart Hospital /ID# 257999
🇰🇷Hwaseong, Gyeonggido, Korea, Republic of
The Second Affiliated Hospital of Guangzhou Medical University /ID# 258638
🇨🇳Guangzhou, Guangdong, China
Usuda Clinic Of Internal Medicine /ID# 260422
🇯🇵Setagaya-ku, Tokyo, Japan
Tokyo Headache Clinic /ID# 258534
🇯🇵Shibuya-ku, Tokyo, Japan
Nagaseki Headache Clinic /ID# 259214
🇯🇵Kai, Yamanashi, Japan
The Affiliated Hospital of Guizhou Medical University /ID# 259536
🇨🇳Guiyang, Guizhou, China
Hainan General Hospital /ID# 259548
🇨🇳Haikou, Hainan, China
The Third Xiangya Hospital of Central South University /ID# 258787
🇨🇳Changsha, Hunan, China
The First Hospital of Jilin University /ID# 259585
🇨🇳Changchun, Jilin, China
Chonnam National University Hospital /ID# 259154
🇰🇷동구, Jeonranamdo, Korea, Republic of
Nowon Eulji Medical Center, Eulji University /ID# 258000
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Seoul National University Hospital /ID# 258002
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Kangbuk Samsung Hospital /ID# 258001
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Yonsei University Health System Severance Hospital /ID# 257998
🇰🇷Seoul, Korea, Republic of
Vitamed Galaj i Cichomski Sp.j. /ID# 258278
🇵🇱Bydgoszcz, Kujawsko-pomorskie, Poland
Athleticomed Sp. z o.o /ID# 258253
🇵🇱Bydgoszcz, Kujawsko-pomorskie, Poland
Indywidualna Praktyka Lekarska dr hab. med. Anna Szczepanska-Szerej /ID# 258281
🇵🇱Lublin, Lubelskie, Poland
Linden Sp. z o.o. sp.k. /ID# 258283
🇵🇱Krakow, Malopolskie, Poland
Instytut Zdrowia Dr Boczarska Jedynak /ID# 258248
🇵🇱Oświęcim, Malopolskie, Poland
Centrum Badan Klinicznych PI-House sp. z o.o. /ID# 258250
🇵🇱Gdansk, Pomorskie, Poland
Silmedic Sp. z o.o. /ID# 258249
🇵🇱Katowice, Slaskie, Poland
Solumed Centrum Medyczne /ID# 258288
🇵🇱Poznan, Wielkopolskie, Poland
Clinical Research Center Sp. z.o.o. Medic-R sp. k /ID# 258268
🇵🇱Poznan, Wielkopolskie, Poland
MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak /ID# 258287
🇵🇱Wroclaw, Poland
Unidade Local de Saude do Alto Ave, EPE /ID# 257986
🇵🇹Guimaraes, Braga, Portugal
Unidade Local de Saude de Almada-Seixal, EPE /ID# 257987
🇵🇹Almada, Portugal
Hospital da Luz Lisboa /ID# 257983
🇵🇹Lisboa, Portugal
Unidade Local de Saude de Santa Maria, EPE /ID# 257989
🇵🇹Lisboa, Portugal
Unidade Local de Saude da Arrabida, EPE /ID# 258139
🇵🇹Setubal, Portugal
University Hospital Bratislava - Hospital ak. L. Derera /ID# 257947
🇸🇰Bratislava, Bratislavsky Kraj, Slovakia
Neurologicka a algeziologicka ambulancia, SANERA /ID# 259176
🇸🇰Prešov, Presovsky Kraj, Slovakia
Liptovska nemocnica s poliklinikou MUDr. Ivana Stodolu Liptovsky Mikulas /ID# 258315
🇸🇰Liptovsky Mikulas, Zilinsky Kraj, Slovakia
MUDr. Beata Dupejova neurologicka ambulancia s.r.o. /ID# 257901
🇸🇰Banska Bystrica, Slovakia
Univerzitna nemocnica - Nemocnica svateho Michala a.s. /ID# 257909
🇸🇰Bratislava, Slovakia
Poliklinika Bezrucova (Cliniq s.r.o.) /ID# 257961
🇸🇰Bratislava, Slovakia
Hospital Universitario Marques de Valdecilla /ID# 257658
🇪🇸Santander, Cantabria, Spain
Clinica Universidad de Navarra - Pamplona /ID# 257656
🇪🇸Pamplona, Navarra, Spain
Hospital Universitario Vall d'Hebron /ID# 257652
🇪🇸Barcelona, Spain
Hospital Universitario La Paz /ID# 257654
🇪🇸Madrid, Spain
Hospital Universitario Virgen del Rocio /ID# 257657
🇪🇸Sevilla, Spain
Hospital Universitario y Politecnico La Fe /ID# 257655
🇪🇸Valencia, Spain
Hospital Clinico Universitario de Valladolid /ID# 257653
🇪🇸Valladolid, Spain
Karolinska Universitetssjukhuset - Huddinge /ID# 258837
🇸🇪Huddinge, Stockholms Lan, Sweden
Neurology Clinic /ID# 258835
🇸🇪Stockholm, Stockholms Lan, Sweden
Hospital Clinico Universitario Lozano Blesa /ID# 257661
🇪🇸Zaragoza, Spain
CTC EbbePark Linkoping /ID# 261170
🇸🇪Linköping, Sweden
Kuang-Tien General Hospital /ID# 258063
🇨🇳Taichung City, Taichung, Taiwan
Tri-Service General Hospital /ID# 258064
🇨🇳Taipei City, Taiwan
Linkou Chang Gung Memorial Hospital /ID# 259171
🇨🇳Taoyuan City, Taiwan
Skaneuro Privatmottagning /ID# 258833
🇸🇪Lund, Skane Lan, Sweden
North Coast Medical Ltd - Newquay Health Centre /ID# 260019
🇬🇧Newquay, Cornwall, United Kingdom
The Adam Practice /ID# 258190
🇬🇧Poole, Dorset, United Kingdom
Re:Cognition Health Birmingham /ID# 258186
🇬🇧Birmingham, United Kingdom
Optimuskliniken /ID# 258834
🇸🇪Upplands Vasby, Sweden
Taipei Veterans General Hospital /ID# 258062
🇨🇳Taipei City, Taipei, Taiwan
China Medical University Hospital /ID# 258417
🇨🇳Taichung, Taiwan
Re:Cognition Health Bristol /ID# 258187
🇬🇧Bristol, United Kingdom
Royal Primary Care Ashgate /ID# 258923
🇬🇧Derbyshire, United Kingdom
Re:Cognition Health - Guildford /ID# 258188
🇬🇧Guildford, United Kingdom
Primary Care Sheffield /ID# 259448
🇬🇧Sheffield, United Kingdom
St Pancras Clinical Research /ID# 258183
🇬🇧London, United Kingdom
The University of Nottingham Health Service /ID# 259380
🇬🇧Nottingham, United Kingdom
Universitair Ziekenhuis Antwerpen /ID# 257582
🇧🇪Edegem, Antwerpen, Belgium
Universitair Ziekenhuis Brussel /ID# 257584
🇧🇪Jette, Bruxelles-Capitale, Belgium
Jessa Ziekenhuis /ID# 257578
🇧🇪Hasselt, Limburg, Belgium
AZ Sint-Jan Brugge /ID# 257585
🇧🇪Brugge, Belgium
AZ Groeninge /ID# 257586
🇧🇪Kortrijk, Belgium
CHR de la Citadelle /ID# 257587
🇧🇪Liege, Belgium
Gartnavel General Hospital /ID# 259384
🇬🇧Glasgow, Glasgow City, United Kingdom
The Second hospital of Jilin university /ID# 258556
🇨🇳Changchun, Jilin, China
General Hospital of Northern Theater Command /ID# 259556
🇨🇳Shenyang, Liaoning, China
West China Hospital, Sichuan University /ID# 258664
🇨🇳Chengdu, Sichuan, China
Shaanxi Provincial People'S Hospital /ID# 259529
🇨🇳XI An, Shaanxi, China
Second Hospital of Shanxi Medical University /ID# 259669
🇨🇳Taiyuan, Shanxi, China
Tianjin People's Hospital /ID# 258625
🇨🇳Tianjin, Tianjin, China
Tianjin Medical University General Hospital /ID# 259513
🇨🇳Tianjin, Tianjin, China
The second affiliated hospital of Zhejiang University school of medicine /ID# 258860
🇨🇳Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University /ID# 258939
🇨🇳Wenzhou, Zhejiang, China
DADO MEDICAL s.r.o. /ID# 257672
🇨🇿Praha, Czechia
Jávorszky Ödön Kórház /ID# 258969
🇭🇺Vác, Pest, Hungary
Baotou Central Hospital /ID# 258786
🇨🇳Baotou, China
FORBELI s.r.o. /ID# 259019
🇨🇿Prague, Czechia
Fakultni Thomayerova nemocnice /ID# 259021
🇨🇿Praha, Czechia
Neuropraxis Muenchen Sued /ID# 258077
🇩🇪Unterhaching, Bayern, Germany
Cortex Study Center /ID# 259032
🇭🇺Budapest, Hungary
The first people's Hospital Affiliated to Shanghai Jiaotong University /ID# 259554
🇨🇳Shanghai, China
Fakultni Nemocnice Ostrava /ID# 259023
🇨🇿Ostrava, Ostrava-mesto, Czechia
Praglandia /ID# 257667
🇨🇿Prague, Praha 5, Czechia
INEP medical s.r.o. /ID# 257669
🇨🇿Praha, Czechia
Kopfschmerzzentrum - Frankfurt /ID# 258019
🇩🇪Frankfurt am Main, Hessen, Germany
Ambenet Hausarztpraxis /ID# 258075
🇩🇪Leipzig, Sachsen, Germany
Vitos Orthopaedische Klinik Kassel gemeinnuetzige GmbH /ID# 258008
🇩🇪Kassel, Germany
CCR Ostrava, s.r.o. /ID# 257743
🇨🇿Ostrava, Ostrava-mesto, Czechia
Axon Clinical, s.r.o. /ID# 259024
🇨🇿Praha, Czechia
Charite Universitaetsmedizin Berlin - Campus Mitte /ID# 258076
🇩🇪Berlin, Germany
Velocity Clinical Research /ID# 258020
🇩🇪Wiesbaden, Germany
NeuroHK s.r.o. /ID# 257671
🇨🇿Hradec Kralove, Czechia
Clintrial s.r.o. /ID# 257663
🇨🇿Prague 10, Czechia
Vestra Clinics s.r.o. /ID# 259022
🇨🇿Rychnov nad Kneznou, Czechia
Studienzentrum Nord-West /ID# 258024
🇩🇪Westerstede, Niedersachsen, Germany
Universitaetsklinikum Duesseldorf /ID# 258078
🇩🇪Düsseldorf, Nordrhein-Westfalen, Germany
Schmerzklinik Kiel /ID# 258005
🇩🇪Kiel, Schleswig-Holstein, Germany
Universitaetsklinikum Essen /ID# 258023
🇩🇪Essen, Germany
Semmelweis Egyetem /ID# 258546
🇭🇺Budapest, Hungary